GNBT Generex Biotechnology Corp

Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM

Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM

MIRAMAR, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation () (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 2021 at 9:00 AM.

Joseph Moscato, Generex President & Chief Executive Officer stated: “I am excited to give our first shareholder conference call to update investors about the development of our Ii-Key complete vaccine against the SARS-CoV-2 coronavirus that continues to ravage the world. We have completed our ex vivo human trial of COVID-19 patient samples and can confirm that the results of the T cell activation and antibody screen have enabled us to select Ii-Key-SARS-CoV-2 epitopes for our vaccine formulation. I will provide an update on these results as well as the results of our ongoing immunogenicity study that will confirm the commercial viability of our Ii-Key vaccine. In addition, I will update everyone on our progress and timing on the NuGenerex Immuno-Oncology Nasdaq listing now that our third-party valuation analysis has been completed with a value estimated at over $500 million. This third-party valuation report is the last piece of information required to enable us to set the price per share to meet the standards for the Nasdaq. I will also provide a complete corporate update including discussions of our subsidiaries”.

Dial-in instructions for the investor conference call will be announced prior to the meeting date.

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

About NuGenerex Immuno-Oncology

NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines for cancer and infectious disease based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors for the treatment of cancer. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato

646-599-6222

Todd Falls

1-800-391-6755 Extension 222



EN
08/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Generex Biotechnology Corp

 PRESS RELEASE

Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Ann...

Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical, has gained approval for the use of Excellagen® Wound Conforming Matrix from The Malaysian Ministry of Health, its country’s equivalent to the U.S. FDA MIRAMAR, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation () (OTCQB:GNBT) subsidiary Olaregen Therapeutix announced in May that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive distributor to import, market and sell th...

 PRESS RELEASE

NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Cl...

NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm Ii-Key Immunotherapeutic Vaccine TechnologyIi-Key-SARS-CoV-2 Vaccine Market Potential & International ContractsMarket Potential for AE37 (Ii-Key-HER2) Immunotherapeutic Vaccine for breast, prostate, and bladder cancers MIRAMAR, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO – ), a subsidiary of Generex Biotechnology Corporation () (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solution...

 PRESS RELEASE

Generex Biotechnology Subsidiary NuGenHealth Contracts with Westside M...

Generex Biotechnology Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Patient Monitoring (RPM) Services NuGenHealth Software as a Service (SaaS) platform that enables their clients to monitor the health and wellbeing of their patient population.Westside Medicine & Cardiology, Inc. is a professional corporation that engages medical providers who are duly licensed in Ohio to provide primary care, cardiology, and RPM services. MIRAMAR, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation () (OTCQB:GNBT) (“Generex” or the “Com...

 PRESS RELEASE

Generex Posts Recording of May 6 Shareholder Conference Call Highlight...

Generex Posts Recording of May 6 Shareholder Conference Call Highlighting its Ii-Key COVID Complete Vaccine™ and its Go-Forward Plans for Revenue Producing Assets Update on Ii-Key-SARS-CoV-2 vaccine programAppointment of Dr. Craig Eagle to be Chairman of the Board of NuGenerex Immuno-Oncology Inc. pending board approval.Re-Launch of Excellagen® in the VA Hospital NetworkLaunch of Remote Patient Monitoring (RPM) Business NuGenHealthUpdate on Partnership & Anticipated Acquisition of AltuCell MIRAMAR, Fla., May 10, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation () (OTCQB:GNBT) (...

 PRESS RELEASE

Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida He...

Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient Monitoring (RPM) Services NuGenHealth Software as a Service (SaaS) platform that enables their clients to monitor the health and wellbeing of their patient population.Florida Health Care Associates is a professional corporation that engages medical providers who are duly licensed in Florida to provide primary care and RPM services (/home.htm) MIRAMAR, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation () (OTCQB:GNBT) (“Generex” or the “Company”), an i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch